TITLE

Breaking into bone biology: serotonin's secrets

AUTHOR(S)
Rosen, Clifford J
PUB. DATE
February 2009
SOURCE
Nature Medicine;Feb2009, Vol. 15 Issue 2, p145
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the effect serotonin has on bone mass. It states that patients that were prescribed selective serotonin reuptake inhibitors to treat depression have a lower bone mineral density than those on tricyclic antidepressants like amitriptyline. It mentions that research on depression examines the role of the hypothalamus in regulating bone turnover and suggests that depression is harmful for the skeleton.
ACCESSION #
36386720

 

Related Articles

  • Long term pharmacotherapy of depression. Edwards, J. Guy // BMJ: British Medical Journal (International Edition);04/18/98, Vol. 316 Issue 7139, p1180 

    Editorial. States that the rates of morbidity, recurrence and death among patients treated for depression have highlighted the importance of long term psychological and pharmacological treatment. Distinction between continuation and maintenance treatment; Benefits of long term drug treatment;...

  • Antidepressants and anxiolytics. Vallone, Doris C.; Chase, Sandra; Cerrato, Paul L. // RN;Jul97, Vol. 60 Issue 7, p27 

    Focuses on how antidepressants work by blocking a process called reuptake. How serotonin elevates moods and helps regulate sleeping patterns; What patients can expect when taking tracyclics; Increasing popularity of selective serotonin reuptake inhibitors.

  • ACP treatment guideline for antidepressants.  // Infectious Disease Alert;Jan2009 Pharmacology Watch, p2 

    The article presents the practice guideline issued by the American College of Physicians (ACP) in January 2009 for the use of antidepressants for treatment of depressive disorder. The guideline covers the use of second-generation antidepressants like fluoxetine (Prozac), duloxetine (Cymbalta)...

  • Vortioxetine approved for major depressive disorder.  // WHO Drug Information;2013, Vol. 27 Issue 4, p359 

    The article discusses the U.S. Food and Drug Administration's (FDA) approval of vortioxetine for the treatment of adults with major depressive disorder.

  • Tricyclics, SSRIs don't harm the fetus.  // Modern Medicine;Mar97, Vol. 65 Issue 3, p5 

    Focuses on the results of a Canadian study indicating that women who do not require drug therapy for depression during pregnancy can take a tricyclic antidepressant or a selective serotonin reuptake inhibitor (SSRI) without worrying about harming their child. Absence of language, behavior or...

  • Formulary Restriction of Selective Serotonin Reuptake Inhibitors for Depression: Potential Pitfalls. Hensley, P.L.; Nurnberg, H.G. // PharmacoEconomics;Oct2001, Vol. 19, p973 

    The American healthcare market is currently estimated at more than $US900 billion with double digit rising costs per year. Psychotropic agent costs have more than kept pace with market increases. Medication acquisition costs are an obvious focus for limiting costs in various care systems....

  • Clinical Q&A. Cicero, Lorraine A.; Pareddy, Satyapal R. // Drug Topics;5/5/97, Vol. 141 Issue 9, p49 

    Answers a query on whether selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCA) can be used safely in the treatment of depression. Causes of symptoms of depression; Two perspectives in the concomitant use of SSRIs and TCAs.

  • Antidepressant Treatment Strategies in the Perinatal Period with a Focus on SSRI use. SAATCİOĞLU, Ömer; Buket TOMRUK, Nesrin // Archives of Neuropsychiatry / Noropsikiatri Arsivi;Mar2013, Vol. 50 Issue 1, p93 

    A letter to the editor is presented which is concerned with antidepressant treatment strategies in the perinatal period with a focus on selective serotonin reuptake inhibitors.

  • Vortioxetine (Brintellix) for the Treatment of Depression. MAGOVERN, MEGAN K.; DEGEORGE, KATHARINE C. // American Family Physician;3/1/2015, Vol. 91 Issue 5, p325 

    The article offers information on the use of antidepressant, vortioxetine or Brintellix for the treatment of depression. Topics discussed include the function of vortioxetine as both a serotonin receptor agonist and antagonist, safety profile of vortioxetine, tolerability and effectiveness, the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics